Lee KyuHo, Lee Kyoung-Bun, Jung Hae Yoen, Yi Nam-Joon, Lee Kwang-Woong, Suh Kyung-Suk, Jang Ja-June
Department of Pathology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, South Korea.
Department of Surgery, Seoul National University College of Medicine, Seoul, 110-744, South Korea.
BMC Cancer. 2017 Jun 23;17(1):441. doi: 10.1186/s12885-017-3431-1.
The Hippo pathway plays a vital role in liver regeneration and development by determining cellular lineage and regulating cell proliferation and apoptosis. In this study, we aimed to assess the role of the Hippo pathway in hepatic carcinogenesis and morphogenesis by examining Yes-associated protein 1 (YAP1) expression in the spectrum of hepatic carcinomas based on cellular lineage.
We examined 913 primary hepatic carcinomas, including hepatocellular carcinomas (HCCs), combined hepatocellular and cholangiocarcinomas (cHC-CCAs), intrahepatic cholangiocarcinomas (IHCCAs) and perihilar extrahepatic bile duct carcinomas (EHBCAs). Our study group was categorized into 8 disease groups, based on histological diagnosis and cytokeratin 19 (CK19) expression, and immunohistochemistry was used to detect and compare YAP1 expression levels between the groups. The eight disease groups we identified were: 1) CK19(-) HCC, 2) CK19(-) scirrhous HCC, 3) CK19(+) HCC, 4) stem cell feature of cHC-CCA, 5) classical cHC-CCA, 6) cholangiolocellular IHCCA, 7) non-cholangiolocellular IHCCA, and 8) EHBCA.
Positive rates of YAP1 were the highest in the EHBCA group (21%). CK19(+) HCC and non-cholangiolocellular IHCCA groups also showed high expression levels (10% -11%), while the CK19 (-) HCC, CK19 (-) scirrhous HCC, cHC-CCA, and cholangiolocellular IHCCA groups showed low expression levels, ranging between 0% and 5%. Survival analysis, restricted to pT1 stage HCCs and IHCCAs, showed poor overall survival for YAP1(+) IHCCA patients (39 ± 17 vs. 109 ± 10 months, mean ± SD, log rank p-value 0.005). For HCCs, a trend of poor progression-free survival for YAP1(+) HCCs was observed (39 ± 18 vs. 81 ± 5 months, mean ± SD, log rank p-value 0.205) CONCLUSIONS: YAP1 activation was more commonly found in CCAs than in pure HCCs. However, a differing pattern of YAP1 expression between cHC-CCAs and CK19(+) HCCs and the poor prognosis of YAP1 positive hepatic carcinomas suggests that YAP1 may have a preferential role in aggressive tumor behavior, rather than in the determination of cellular lineage in hepatic carcinomas.
河马通路通过决定细胞谱系以及调节细胞增殖和凋亡,在肝脏再生和发育中发挥着至关重要的作用。在本研究中,我们旨在通过基于细胞谱系检查原发性肝癌谱系中Yes相关蛋白1(YAP1)的表达,来评估河马通路在肝癌发生和形态发生中的作用。
我们检查了913例原发性肝癌,包括肝细胞癌(HCC)、肝细胞胆管癌合并症(cHC-CCA)、肝内胆管癌(IHCCA)和肝门部肝外胆管癌(EHBCA)。我们的研究组根据组织学诊断和细胞角蛋白19(CK19)表达分为8个疾病组,并使用免疫组织化学检测和比较各组之间的YAP1表达水平。我们确定的8个疾病组为:1)CK19(-)HCC,2)CK19(-)硬化性HCC,3)CK19(+)HCC,4)cHC-CCA的干细胞特征,5)经典cHC-CCA,6)胆管细胞性IHCCA,7)非胆管细胞性IHCCA,8)EHBCA。
YAP1阳性率在EHBCA组中最高(21%)。CK19(+)HCC和非胆管细胞性IHCCA组也显示出高表达水平(10% - 11%),而CK19(-)HCC、CK19(-)硬化性HCC、cHC-CCA和胆管细胞性IHCCA组显示出低表达水平,范围在0%至5%之间。仅限于pT1期HCC和IHCCA的生存分析显示,YAP1(+)IHCCA患者的总生存期较差(39±17 vs. 109±10个月,平均值±标准差,对数秩p值0.005)。对于HCC,观察到YAP1(+)HCC的无进展生存期有较差的趋势(39±18 vs. 81±5个月,平均值±标准差,对数秩p值0.205)。结论:YAP1激活在CCA中比在单纯HCC中更常见。然而,cHC-CCA与CK19(+)HCC之间YAP1表达模式的差异以及YAP1阳性肝癌的不良预后表明,YAP1可能在侵袭性肿瘤行为中起优先作用,而不是在肝癌细胞谱系的决定中起作用。